Danaher (NYSE:DHR) Price Target Raised to $264.00

Danaher (NYSE:DHR) had its price objective increased by investment analysts at Credit Suisse Group from $260.00 to $264.00 in a note issued to investors on Thursday, AR Network reports. The brokerage presently has an “outperform” rating on the conglomerate’s stock. Credit Suisse Group’s target price points to a potential upside of 10.07% from the company’s previous close.

DHR has been the topic of several other research reports. The Goldman Sachs Group initiated coverage on shares of Danaher in a research note on Wednesday, December 2nd. They issued a “buy” rating and a $250.00 target price on the stock. Royal Bank of Canada lowered shares of Danaher from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $273.00 to $234.00 in a report on Wednesday, November 25th. KeyCorp started coverage on Danaher in a research note on Monday, November 9th. They issued an “overweight” rating and a $280.00 price target on the stock. Robert W. Baird raised their price target on Danaher from $205.00 to $252.00 and gave the stock an “outperform” rating in a research report on Friday, October 23rd. Finally, Needham & Company LLC upped their price objective on Danaher from $209.00 to $272.00 in a report on Tuesday, October 27th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $225.38.

Shares of NYSE DHR opened at $239.84 on Thursday. Danaher has a 12-month low of $119.60 and a 12-month high of $248.32. The firm’s 50-day simple moving average is $225.79 and its 200 day simple moving average is $213.85. The company has a quick ratio of 1.68, a current ratio of 2.08 and a debt-to-equity ratio of 0.63. The company has a market cap of $170.38 billion, a price-to-earnings ratio of 48.55, a price-to-earnings-growth ratio of 2.83 and a beta of 0.74.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Thursday, October 22nd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.36. The business had revenue of $5.90 billion during the quarter, compared to analyst estimates of $5.51 billion. Danaher had a net margin of 18.05% and a return on equity of 12.94%. Danaher’s revenue for the quarter was up 17.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.06 earnings per share. On average, equities analysts expect that Danaher will post 6.03 earnings per share for the current year.

In other Danaher news, SVP Daniel Raskas sold 28,389 shares of the business’s stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $234.50, for a total transaction of $6,657,220.50. Following the sale, the senior vice president now directly owns 38,850 shares of the company’s stock, valued at approximately $9,110,325. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Robert S. Lutz sold 24,594 shares of the stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $233.19, for a total transaction of $5,735,074.86. Following the transaction, the chief accounting officer now owns 43,544 shares of the company’s stock, valued at $10,154,025.36. The disclosure for this sale can be found here. Insiders have sold 107,385 shares of company stock valued at $25,081,562 over the last ninety days. 11.70% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Provident Wealth Management LLC bought a new position in Danaher during the third quarter worth about $27,000. Price Wealth LLC raised its stake in Danaher by 75.6% in the 3rd quarter. Price Wealth LLC now owns 137 shares of the conglomerate’s stock valued at $30,000 after acquiring an additional 59 shares during the period. Newfound Research LLC bought a new stake in Danaher in the 3rd quarter valued at $37,000. Atlas Private Wealth Management acquired a new stake in Danaher during the 3rd quarter valued at $41,000. Finally, Oakworth Capital Inc. boosted its position in Danaher by 48.9% during the third quarter. Oakworth Capital Inc. now owns 198 shares of the conglomerate’s stock worth $43,000 after purchasing an additional 65 shares during the period. 69.16% of the stock is owned by institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Featured Story: The mechanics of the bid-ask spread in trading